This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Artificial intelligence is now designing custom proteins in seconds—a process that once took years—paving the way for cures to diseases like cancer and antibiotic-resistant infections. Australian scientists have joined this biomedical frontier by creating bacteria-killing proteins with AI. Their new platform, built by a team of biologists and computer scientists, is part of a global movement to democratize and accelerate protein design for medical breakthroughs.
Skip to main content CONTINUE TO SITE ➞ Dont miss tomorrows biopharma industry news Let BioPharma Dives free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy.
Xiaoqiang He, Shihan Zeng, Yalei Wen, Tao Yang, Chaoming Huang, Yifang Li, Zhang Zhang, Ke Ding, Tongzheng Liu, Yi Tan, and Zhengqiu Li J. Am. Chem. Soc. 2025 , 147 , 25 , 21512–21525 [link] Targeted protein degradation (TPD) has emerged as a promising therapeutic strategy for treating various diseases. However, current small molecule degraders predominantly rely on a limited set of E3 ubiquitin ligases, such as CRBN and VHL, which restricts their applications.
In Adobe’s 2025 AI and Digital Trends report, one message rings loud and clear: the convergence of marketing and IT is essential to digital success. As AI becomes increasingly embedded in customer experience strategies, marketing and IT leaders must collaborate closely to unlock its full potential. The Rise of Agentic AI One of the most transformative ideas in the report is the rise of agentic AI, autonomous systems that collaborate across platforms to deliver hyper-personalized, real-time exper
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Zoledronic acid was identified as a lead hit targeting ZNF726 activity, inhibiting its proliferative effects on breast cancer cells. Zoledronic acid inhibits cellular cholesterol level through the inhibition of ZNF726 activity in breast cancer cells. Nine phytochemicals were identified from docking studies that might be used as potential therapeutics for targeting ZNF726 activity.
Prime editing treats childhood brain disease in mice By Corie Lok July 21, 2025 Breadcrumb Home Prime editing treats childhood brain disease in mice Scientists use a precise form of gene editing called prime editing to correct the most common genetic mutations that cause alternating hemiplegia of childhood, a rare and severe neurological disorder that begins in infancy.
Clinical trials are expensive, slow and often limited by outdated design constraints. Placebo arms, in particular, create ethical and logistical hurdles, especially in areas like rare disease and oncology. Digital twins offer a way forward. They offer patient-specific outcome predictions, generated using machine learning models trained on real historical clinical data.
Signup to get articles personalized to your interests!
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Clinical trials are expensive, slow and often limited by outdated design constraints. Placebo arms, in particular, create ethical and logistical hurdles, especially in areas like rare disease and oncology. Digital twins offer a way forward. They offer patient-specific outcome predictions, generated using machine learning models trained on real historical clinical data.
WEDNESDAY, May 14, 2025 -- Migraines don’t just cause headaches. These attacks often are accompanied by symptoms like light and sound sensitivity, nausea, neck pain and dizziness. What’s more, those non-headache symptoms tend to crop.
When I last wrote about AI on this blog three years ago, I spoke of it being a tool with the potential to transform scientific discovery, but the application I described was primarily theoretical. For AI to be a meaningful tool in R&D, I argued, we needed better sources of truth better data sets that AI tools could query and learn from over time and technology capable of integrating multiples steps into a semi-automated system.
The latest release of the Platform — 25.06 — is now available at platform.opentargets.org. We’re trying something new: tomorrow at 3pm UK time, join our walkthrough and Q&A session on LinkedIn. The team will showcase the new features and data in this release, and then will answer your questions about the release and the Platform.
By Cody Tranbarger, EIR at Atlas Venture, as part of the From The Trenches feature of LifeSciVC Its an interesting time to be thinking about space. Just a few months ago, SpaceX captivated and inspired the world by catching a reusable rocket booster with mechanical chopsticks for the first time. Meanwhile, humanitys march toward a multi-planetary future continues, with Mars on the itinerary for the 2030s (unless youre on Elon time ).
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
A cutting-edge gene therapy has significantly restored hearing in children and adults with congenital deafness, showing dramatic results just one month after a single injection. Researchers used a virus to deliver a healthy copy of the OTOF gene into the inner ear, improving auditory function across all ten participants in the study. The therapy worked best in young children but still benefited adults, with one 7-year-old girl regaining almost full hearing.
Skip to main content CONTINUE TO SITE ➞ Dont miss tomorrows biopharma industry news Let BioPharma Dives free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy.
Xinyuan Wu, Jiayi Pan, Rufeng Fan, Yiwei Zhang, Chao Wang, Guoliang Wang, Jiaxiang Liu, Mengqing Cui, Jinfeng Yue, Rui Jin, Zhiqiang Duan, Mingyue Zheng, Lianghe Mei, Lu Zhou, Minjia Tan, Jing Ai, and Xiaojie Lu Journal of the American Chemical Society 2025 147 (18), 15469-15481 DOI: 10.1021/jacs.5c01712 Covalent small molecule drugs have emerged as a crucial support in precision therapy due to their high selectivity and robust potency.
A mid-sized bank I was consulting with for their data warehouse modernization project finally realized that data isn’t just some necessary but boring stuff the IT department hoards in their digital cave. It’s the new gold, the ticking time bomb of risk, and the bane of every regulatory report that’s ever come back with more red flags than a beach during a shark sighting.
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Computationally guided modifications of centaureidin led to the development of CA4, demonstrating enhanced antioxidant and antitumor activities. Molecular docking and in vitro assays confirm improved binding affinity and cytotoxicity, highlighting CA4's potential as a promising drug candidate for cancer therapy. ABSTRACT The development of novel therapeutic drugs with enhanced efficacy has gained significant attention in recent years.
Researchers devise new way to target and correct disease-related proteins By Leah Eisenstadt January 6, 2025 Breadcrumb Home Researchers devise new way to target and correct disease-related proteins Broad scientists built a diverse library of compounds and found one that stabilizes a dysfunctional protein in Crohns disease, demonstrating their librarys potential to uncover new therapeutic strategies.
It is becoming increasingly evident that generative artificial intelligence (GenAI) is a resourceful tool for helping pharmaceutical companies reduce manual tasks required by clinical trials. However, R&D stakeholders are learning that GenAI underpinned by domain expertise also enables deep dives into the broader long-term potential of their investigational asset(s) as early as the preclinical phase.
WEDNESDAY, May 14, 2025 The U.S. Food and Drug Administration (FDA) plans to review and possibly remove prescription fluoride supplements for children from the market.The FDA announced Tuesday that it intends to conduct the review by Oct. 31, 2.
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Drug resistance remains one of the most pressing challenges in oncology drug development, as it is the leading cause of treatment failure. As researchers look to understand and overcome drug resistance, they need precise, controllable, and scalable models that allow them to isolate and study resistance mechanisms effectively. This article explores the role in vitro models are playing in the fight against drug resistance and explains how they can accelerate the development of successful novel the
Identifying drug patents is crucial for various stakeholders, including researchers, legal professionals, and business strategists. While Google Patents is a widely used tool for searching patent information, it may not be the most effective solution for identifying drug patents. This article explores the limitations of Google Patents in this context and suggests alternative approaches.
BURLINGAME, Calif. — July 8, 2025. Collaborative Drug Discovery (CDD) , the leading provider of data management solutions for the pharmaceutical and biotechnology industries, and deepmirror , the AI drug design platform that empowers chemists to focus on more promising drug molecules, today announced a strategic partnership integrating deepmirror with CDD Vault to enhance drug discovery.
Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response with just one dose. By combining two immune-boosting adjuvants alum and SMNP the vaccine lingers in lymph nodes for nearly a month, encouraging the body to produce a vast array of antibodies. This one-shot strategy could revolutionize how we fight not just HIV, but many infectious diseases.
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to prescribe Lilly’s amyloid-busting drug.
Genhui Xiao, Yumeng Cui, Liangliang Zhou, Chuya Niu, Bing Wang, Jinglan Wang, Shaoyang Zhou, Miaomiao Pan, Chi Kin Chan, Yan Xia, Lan Xu, Yu Lu, Shawn Chen mLife , 2025 DOI: [link] The caseinolytic protease complex ClpP1P2 is crucial for protein homeostasis in mycobacteria and stress response and virulence of the pathogens. Its role as a potential drug target for combating tuberculosis (TB) has just begun to be substantiated in drug discovery research.
You can think of the Model Context Protocol (MCP) as USB for large language models (LLMs), allowing an LLM to interact with a variety of external systems in a uniform manner. It was developed by Anthropic to solve the fundamental problem of getting a text generator (LLM) to perform real-world actions on a user’s behalf. Solving the M x N Problem With a growing number of powerful LLMs (M) and a vast universe of applications and APIs (N) for them to interact with, one would need to develop M
A series of small molecule PD-L1 inhibitors was discovered via optimization of the solvent-interaction region. GJ19 showed the most potent anti-PD-L1 effects with an IC 50 of 32.06 nM. GJ19 (i.p., 15 mg/kg) effectively suppressed tumor growth with a TGI of 56.8% in a B16-F10 melanoma mouse model. ABSTRACT Despite extensive research, the topic of anti-PD-L1 small-molecule inhibitors remains elusive.
Scientists apply optical pooled CRISPR screening to identify potential new Ebola drug targets By Leah Eisenstadt July 24, 2025 Breadcrumb Home Scientists apply optical pooled CRISPR screening to identify potential new Ebola drug targets Combining powerful imaging, perturbational screening, and machine learning, researchers uncover new human host factors that alter Ebola’s ability to infect.
Sujeegar Jeevanandam, an expert with 13 years of experience in life sciences R&D, offers valuable insights into the current state and future trajectory of artificial intelligence in drug discovery. Having previously drawn parallels with industry adoption of electronic lab notebooks in part 1 , this article expands on his vision for the future of the industry, sharing his forward-thinking ideas and practical recommendations.
MONDAY, June 2, 2025 Removing fluoride from the U.S. water supply could result in more than 25 million more decayed teeth in children and teenagers within five years, a new study warns.Thats the equivalent of a decayed tooth for 1 of every 3 kid.
FDA Approves Streamlined Monitoring Requirements and REMS Program Removal for Bristol Myers Squibb’s CAR T Cell Therapies Breyanzi and Abecma, Marking Milestone Toward Expanding Access to Cancer Treatment In a significant regulatory development, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has approved critical label updates for its two chimeric antigen receptor (CAR) T cell therapies— Breyanzi® (lisocabtagene maraleucel; liso-cel) and Abecma® (idecabtage
One of the ultimate aims of protein design has long been to build entirely new enzymes — proteins that perform specific chemical reactions — from scratch. These molecular machines power various cellular processes, from converting sugar into energy to switching genes on and off. Both Cas9 and hydrolases (widely used in the dairy and laundry industries) are also enzymes.
How can you work out the function of a particular gene or protein across different cell types and functions? If you perturb it—modify it and observe the consequences—you can start to unravel what its biological role might be, and determine whether the effects are unique to one cell type or whether they propagate across different cell contexts.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content